Merck, BioMed X extend collaboration in oncology, autoimmunity

By The Science Advisory Board staff writers

May 17, 2021 -- Merck has extended its collaboration with German company BioMed X and will start six additional research projects at the BioMed X Institute. The projects will build on research in oncology -- specifically looking at DNA damage response and RNA splicing -- and autoimmunity -- looking at intestinal epithelial barrier in autoimmune diseases.

The next joint crowdsourcing project will focus on immune senescence and mitochondrial dysfunction in regulatory T cells and other T-cell subsets that are shared in human autoimmunity and aging. Interested parties can submit a project proposal at www.bio.mx/apply before July 11.

If you like this content, please share it with a colleague!

Related Reading

Merck, Ridgeback to advance outpatient COVID-19 therapy to phase III trial
Merck and Ridgeback Biotherapeutics have announced they will move forward with a phase III trial of EIDD-2801/MK-4482 (molnupiravir), an oral antiviral...

Merck, Ridgeback anti-COVID-19 agent shows promise in clinical trials
Merck and Ridgeback Biotherapeutics have released results from a phase IIA clinical trial of the investigational oral antiviral agent EIDD-2801/MK-4482...

Merck gets $269M to ramp up COVID-19 vaccine manufacturing
Merck has received about $269 million in U.S. funding to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 vaccines and medicines.

Merck to acquire Pandion for $1.85B
Merck has announced that it will acquire Pandion Therapeutics for $1.85 billion.

Starpharma, Merck collaborate on new ADCs
Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's...